Dr. William Makis promotes an experimental “Hybrid Orthomolecular Cancer Protocol” that centers on repurposed antiparasitic drugs (especially ivermectin and mebendazole/fenbendazole), combined with nutrient-based (orthomolecular) support and structured dosing cycles tailored to cancer aggressiveness.
Below is a neutral, descriptive overview of what his protocol involves, how it is structured, and the mechanisms he cites for each component.
Background on Dr. Makis and His Protocol
Dr. William Makis is a Canadian-trained physician described as a radiologist and oncologist with numerous peer‑reviewed publications, who now focuses on alternative and repurposed‑drug cancer therapies. He has outlined a “Hybrid Orthomolecular Cancer Protocol” in articles, interviews, and a 2024 paper in the Journal of Orthomolecular Medicine, co‑authored with Dr. Ilyes Baghli and Dr. Paul Marik.
The protocol is presented as a structured regimen using repurposed antiparasitic drugs together with vitamins, botanicals, and metabolic strategies, and is typically used as an adjunct to or after standard therapies, based on the materials describing it.
Core Concept: Mitochondrial–Stem Cell Focus
The protocol is built around what Makis calls the mitochondrial‑stem cell connection (MSCC) in cancer biology. The key conceptual pillars he emphasizes include:
- Many cancer cells rely on anaerobic fermentation rather than oxidative phosphorylation (the “Warburg effect”), which the protocol seeks to disrupt.
- Cancer stem cells (CSCs) are described as driving metastasis, recurrence, and treatment resistance, so several agents are chosen for their reported activity against CSCs.
- Mitochondrial function is targeted to promote apoptosis (programmed cell death), autophagy, and decreased glycolysis in tumor cells.
Antiparasitic agents such as ivermectin and benzimidazoles are framed as tools to restore more normal mitochondrial function in cancer cells, restrict fermentable substrates (glucose, glutamine), and target CSCs.
Overall Treatment Structure and Cycles
Protocol descriptions emphasize a cyclical structure and ongoing laboratory monitoring.
- Typical duration: often described as 3 months as an initial course.
- Cycles: commonly structured as 3 weeks “on” and 1 week “off” for the overall protocol.
- Within cycles, several drugs use “6 days on, 1 day off” patterns.
- Stratification by cancer grade:
Regular monitoring of liver and kidney function, plus blood counts, is built into the protocol descriptions, and many agents are taken with fatty meals to enhance bioavailability.
Ivermectin Component
Ivermectin is presented as a central pharmacologic pillar in Makis’ protocol.
Proposed Mechanisms
Materials describing the protocol summarize several laboratory‑level effects:
- Promotes apoptosis and autophagy via mitochondrial pathways.
- Suppresses glycolysis (reducing cancer cells’ ability to use glucose).
- Interferes with signal pathways implicated in cancer stem cell survival.
- Exhibits anti‑inflammatory and antiviral properties, which Makis also cites as beneficial in the overall cancer milieu.
Preclinical experiments (in vitro and animal models) are highlighted in his educational materials as showing reductions in tumor volume and activity against CSCs.
Dosing Framework (Weight‑Based)
The JASE Medical summary of his published regimen provides the following general ranges, scaled to body weight and cancer grade (example: 1 mg/kg for a 70 kg person = 70 mg):
- Low‑grade cancers, remission support, or prophylaxis:
- Around 0.5 mg/kg, three times weekly (e.g., Monday/Wednesday/Friday).
- Intermediate‑grade cancers:
- Around 1 mg/kg three times weekly, or 0.5–1 mg/kg daily in more challenging cases.
- High‑grade or “turbo” cancers:
Administration Pattern
- Schedule: typically 6 days on, 1 day off.
- Taken with food, often with fat to improve absorption.
- Some descriptions state that long‑term dosing up to roughly 2 mg/kg daily has been reported as tolerated.
Mebendazole / Fenbendazole Component
Benzimidazoles (mebendazole for humans, fenbendazole often described as a veterinary analogue) are the second major pharmacologic column of the protocol.
Proposed Mechanisms
Protocol descriptions and related literature attribute several properties to this class:
- Impaired microtubule assembly, affecting cancer cell division.
- Restriction of glucose and glutamine uptake.
- Activation of tumor suppressor pathways such as p53.
- Activity against CSCs and synergy with ivermectin in preclinical contexts.
A 2025 PubMed case series on fenbendazole (outside Makis’ own clinic) describes three advanced cancer cases (breast, prostate, melanoma) in which patients incorporated fenbendazole alongside other non‑chemotherapy treatments and achieved complete or near‑complete remissions, with good tolerance during 11‑ to 36‑month follow‑up.
Dosing Framework (Flat Doses)
The JASE Medical summary of Makis’ protocol outlines indicative dosing tiers:
- Low‑grade disease:
- Intermediate‑grade disease:
- High‑grade/metastatic disease:
Administration and Support
- Taken after meals, with fats to aid absorption.
- Frequently paired with milk thistle (silymarin) in the 250–350 mg range as hepatic support.
- Routine blood work (including liver enzymes) is emphasized in published descriptions.
Orthomolecular / Nutrient Components
The protocol is termed “Hybrid Orthomolecular” because it integrates nutrient‑based and metabolic interventions with repurposed drugs. While specific combinations can vary, materials summarizing his work highlight:
- Vitamins and antioxidants:
- Phytochemicals and oils:
- Liver support:
- Metabolic environment:
- Dietary guidance in Makis‑related content typically emphasizes lowering glucose and glutamine availability, aligning with the Warburg‑effect focus, though detailed diet protocols are usually individualized.
These orthomolecular elements are presented as complementary to enhance mitochondrial function, reduce inflammation, and support detoxification while the repurposed drugs target CSCs and tumor metabolism.
Cancer Types and Reported Use Cases
Descriptions of Makis’ work reference a range of cancer types in which he or others have applied high‑dose ivermectin/benimidazole combinations.
Examples drawn from case‑style reports and community sharing include:
- Prostate cancer: Reports describe responses and remissions under his regimen.
- Lymphomas: Cited among cancers where his clinic has seen notable responses.
- Pancreatic cancer: A frequently referenced story involves a 40‑year‑old with stage 4 pancreatic cancer; after starting a high‑dose ivermectin and fenbendazole protocol under Makis’ guidance, tumor markers reportedly dropped from about 28,400 to around 2,600, with symptomatic improvement and anticipation of clear scans.
- Other solid tumors: Protocol summaries mention applications in aggressive or “turbo” cancers, a term he uses for rapidly progressing malignancies, often in a post‑vaccine context.
These are presented in his ecosystem as illustrative examples of how the protocol may be used across different cancer types and stages.
Integration With Other Therapies
Protocol descriptions and allied content emphasize that many patients use these regimens alongside other treatments rather than in complete isolation.
- Combination with non‑chemotherapy modalities:
- Use after or alongside conventional cancer care:
- Emerging formal trials:
- Outside of Makis himself, a small trial at Cedars‑Sinai is studying ivermectin plus immunotherapy in metastatic breast cancer (clinical trial NCT05318469), illustrating broader interest in ivermectin’s potential role in oncology.
Contact, Access, and Information Channels
For patients seeking more detail on these regimens, several sources list contact points connected to Makis’ work:
- Substack: makismd.substack.com is cited as a place where he shares protocol information and commentary.
- Direct contact: Some podcast and resource pages list an email such as makisw79@yahoo.com for individuals seeking dosing protocols or consultations.
- Pharmacies: At least one podcast episode points listeners to online pharmacies for ivermectin and mebendazole, including a discount code associated with his name, indicating defined supply channels for his followers.
- Educational summaries: The JASE Medical educational article provides one of the more detailed written overviews of Makis’ “Hybrid Orthomolecular” protocol, including rationales, dosing bands by cancer grade, and typical cycle structures.
Evidence Context (Descriptive Only)
Staying strictly descriptive, the materials around the protocol characterize the evidence base in a specific way:
- Preclinical:
- In‑vitro and animal studies are frequently cited for ivermectin’s and benzimidazoles’ anticancer effects, including tumor volume reduction and CSC targeting.
- Case reports and series:
- Clinical trials:
- A breast cancer trial combining ivermectin with immunotherapy is underway at Cedars‑Sinai, reflecting formal interest in ivermectin as an adjunct in oncology.
- Clinical practice and testimonials:
- Articles summarizing Makis’ work mention “hundreds of testimonials” from his clinic for cancers such as prostate, lymphoma, and pancreatic cancer.
These points describe how the protocol’s own ecosystem portrays its scientific and clinical grounding, without assessing or grading the strength of that evidence.
Leave a Reply
You must be logged in to post a comment.